vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and Waystar Holding Corp. (WAY). Click either name above to swap in a different company.

Waystar Holding Corp. is the larger business by last-quarter revenue ($313.9M vs $202.1M, roughly 1.6× CORCEPT THERAPEUTICS INC). Waystar Holding Corp. runs the higher net margin — 13.8% vs 12.0%, a 1.8% gap on every dollar of revenue. On growth, Waystar Holding Corp. posted the faster year-over-year revenue change (22.4% vs 11.1%). Waystar Holding Corp. produced more free cash flow last quarter ($90.3M vs $38.4M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 15.7%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Waystar Holding Corp is a leading provider of integrated healthcare payment and revenue cycle management solutions. It serves healthcare providers, health systems, and payers across the United States, offering tools that streamline billing, claims processing, patient payment collection, and revenue optimization to reduce administrative burdens and improve financial performance for healthcare organizations.

CORT vs WAY — Head-to-Head

Bigger by revenue
WAY
WAY
1.6× larger
WAY
$313.9M
$202.1M
CORT
Growing faster (revenue YoY)
WAY
WAY
+11.3% gap
WAY
22.4%
11.1%
CORT
Higher net margin
WAY
WAY
1.8% more per $
WAY
13.8%
12.0%
CORT
More free cash flow
WAY
WAY
$51.9M more FCF
WAY
$90.3M
$38.4M
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
15.7%
WAY

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
WAY
WAY
Revenue
$202.1M
$313.9M
Net Profit
$24.3M
$43.3M
Gross Margin
98.7%
Operating Margin
2.2%
25.6%
Net Margin
12.0%
13.8%
Revenue YoY
11.1%
22.4%
Net Profit YoY
-21.0%
47.9%
EPS (diluted)
$0.20
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
WAY
WAY
Q1 26
$313.9M
Q4 25
$202.1M
$303.5M
Q3 25
$207.6M
$268.7M
Q2 25
$194.4M
$270.7M
Q1 25
$157.2M
$256.4M
Q4 24
$181.9M
$244.1M
Q3 24
$182.5M
$240.1M
Q2 24
$163.8M
$234.5M
Net Profit
CORT
CORT
WAY
WAY
Q1 26
$43.3M
Q4 25
$24.3M
$20.0M
Q3 25
$19.7M
$30.6M
Q2 25
$35.1M
$32.2M
Q1 25
$20.5M
$29.3M
Q4 24
$30.7M
$19.1M
Q3 24
$47.2M
$5.4M
Q2 24
$35.5M
$-27.7M
Gross Margin
CORT
CORT
WAY
WAY
Q1 26
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Operating Margin
CORT
CORT
WAY
WAY
Q1 26
25.6%
Q4 25
2.2%
19.4%
Q3 25
4.9%
22.4%
Q2 25
13.7%
24.0%
Q1 25
2.2%
25.4%
Q4 24
13.9%
21.8%
Q3 24
25.5%
11.3%
Q2 24
21.7%
3.5%
Net Margin
CORT
CORT
WAY
WAY
Q1 26
13.8%
Q4 25
12.0%
6.6%
Q3 25
9.5%
11.4%
Q2 25
18.1%
11.9%
Q1 25
13.1%
11.4%
Q4 24
16.9%
7.8%
Q3 24
25.9%
2.3%
Q2 24
21.7%
-11.8%
EPS (diluted)
CORT
CORT
WAY
WAY
Q1 26
$0.42
Q4 25
$0.20
$0.10
Q3 25
$0.16
$0.17
Q2 25
$0.29
$0.18
Q1 25
$0.17
$0.16
Q4 24
$0.25
$0.18
Q3 24
$0.41
$0.03
Q2 24
$0.32
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
WAY
WAY
Cash + ST InvestmentsLiquidity on hand
$372.2M
$34.3M
Total DebtLower is stronger
$13.5M
Stockholders' EquityBook value
$647.8M
$3.9B
Total Assets
$836.7M
$5.8B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
WAY
WAY
Q1 26
$34.3M
Q4 25
$372.2M
$61.4M
Q3 25
$421.7M
$421.1M
Q2 25
$342.2M
$290.3M
Q1 25
$322.8M
$224.0M
Q4 24
$383.3M
$182.1M
Q3 24
$380.3M
$127.1M
Q2 24
$473.2M
$68.4M
Total Debt
CORT
CORT
WAY
WAY
Q1 26
$13.5M
Q4 25
$1.5B
Q3 25
Q2 25
Q1 25
Q4 24
$1.2B
Q3 24
Q2 24
Stockholders' Equity
CORT
CORT
WAY
WAY
Q1 26
$3.9B
Q4 25
$647.8M
$3.9B
Q3 25
$631.9M
$3.2B
Q2 25
$635.8M
$3.2B
Q1 25
$683.3M
$3.1B
Q4 24
$679.6M
$3.1B
Q3 24
$638.8M
$3.1B
Q2 24
$596.2M
$2.9B
Total Assets
CORT
CORT
WAY
WAY
Q1 26
$5.8B
Q4 25
$836.7M
$5.8B
Q3 25
$823.6M
$4.7B
Q2 25
$801.7M
$4.7B
Q1 25
$846.5M
$4.6B
Q4 24
$840.6M
$4.6B
Q3 24
$784.3M
$4.5B
Q2 24
$714.6M
$4.6B
Debt / Equity
CORT
CORT
WAY
WAY
Q1 26
0.00×
Q4 25
0.38×
Q3 25
Q2 25
Q1 25
Q4 24
0.40×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
WAY
WAY
Operating Cash FlowLast quarter
$38.4M
$84.9M
Free Cash FlowOCF − Capex
$38.4M
$90.3M
FCF MarginFCF / Revenue
19.0%
28.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
1.96×
TTM Free Cash FlowTrailing 4 quarters
$314.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
WAY
WAY
Q1 26
$84.9M
Q4 25
$38.4M
$66.6M
Q3 25
$54.5M
$82.0M
Q2 25
$43.9M
$96.8M
Q1 25
$5.1M
$64.2M
Q4 24
$59.3M
Q3 24
$73.8M
$78.8M
Q2 24
$41.2M
$15.4M
Free Cash Flow
CORT
CORT
WAY
WAY
Q1 26
$90.3M
Q4 25
$38.4M
$57.2M
Q3 25
$76.2M
Q2 25
$43.9M
$91.0M
Q1 25
$5.0M
$58.8M
Q4 24
$59.2M
Q3 24
$72.2M
$70.2M
Q2 24
$40.8M
$8.6M
FCF Margin
CORT
CORT
WAY
WAY
Q1 26
28.8%
Q4 25
19.0%
18.9%
Q3 25
28.3%
Q2 25
22.6%
33.6%
Q1 25
3.2%
22.9%
Q4 24
32.5%
Q3 24
39.5%
29.2%
Q2 24
24.9%
3.7%
Capex Intensity
CORT
CORT
WAY
WAY
Q1 26
Q4 25
0.0%
3.1%
Q3 25
0.0%
2.2%
Q2 25
0.0%
2.1%
Q1 25
0.1%
2.1%
Q4 24
0.1%
Q3 24
0.9%
3.6%
Q2 24
0.3%
2.9%
Cash Conversion
CORT
CORT
WAY
WAY
Q1 26
1.96×
Q4 25
1.58×
3.33×
Q3 25
2.77×
2.68×
Q2 25
1.25×
3.01×
Q1 25
0.25×
2.20×
Q4 24
1.93×
Q3 24
1.56×
14.56×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

WAY
WAY

Subscription$172.2M55%
Volume-based$139.5M44%

Related Comparisons